TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells.
Thymic stromal lymphopoietin (TSLP) is elevated in asthma and triggers dendritic cell-mediated activation of Th2 inflammatory responses. Although TSLP has been shown to be produced mainly by airway epithelial cells, the regulation of epithelial TSLP expression has not been extensively studied. We investigated the expression of TSLP in cytokine- or TLR ligand-treated normal human bronchial epithelial cells (NHBE). The mRNA for TSLP was significantly up-regulated by stimulation with IL-4 (5.5-fold) and IL-13 (5.3-fold), weakly up-regulated by TNF-alpha, TGF-beta, and IFN-beta, and not affected by IFN-gamma in NHBE. TSLP mRNA was only significantly up-regulated by the TLR3 ligand (dsRNA) among the TLR ligands tested (66.8-fold). TSLP was also induced by in vitro infection with rhinovirus. TSLP protein was detected after stimulation with dsRNA (120 +/- 23 pg/ml). The combination of TNF-alpha and IL-4 produced detectable levels of TSLP protein (40 +/- 13 pg/ml). In addition, TSLP was synergistically enhanced by a combination of IL-4 and dsRNA (mRNA; 207-fold, protein; 325 +/- 75 pg/ml). The induction of TSLP by dsRNA was dependent upon NF-kappaB and IFN regulatory factor 3 (IRF-3) signaling via TLR3 as indicated by a study with small interfering RNA. The potent topical glucocorticoid fluticasone propionate significantly suppressed dsRNA-dependent TSLP production in NHBE. These results suggest that the expression of TSLP is induced in airway epithelial cells by stimulation with the TLR3 ligand and Th2 cytokines and that this response is suppressed by glucocorticoid treatment. This implies that respiratory viral infection and the recruitment of Th2 cytokine producing cells may amplify Th2 inflammation via the induction of TSLP in the asthmatic airway.
Kato
Atsushi
A
Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Favoreto
Silvio
S
Avila
Pedro C
PC
Schleimer
Robert P
RP
D001249:Asthma / Q000276:immunology / Q000503:physiopathology; D001980:Bronchi / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D016207:Cytokines / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D004848:Epithelium / Q000187:drug effects / Q000276:immunology*; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D010850:Picornaviridae Infections / Q000276:immunology; D012333:RNA, Messenger / Q000032:analysis; D011993:Recombinant Fusion Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012229:Rhinovirus / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D051196:Toll-Like Receptor 3 / Q000276:immunology / Q000378:metabolism*; D014162:Transfection; D000094632:Thymic Stromal Lymphopoietin
D016207:Cytokines; D005938:Glucocorticoids; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; C495344:TLR3 protein, human; D051196:Toll-Like Receptor 3; D000094632:Thymic Stromal Lymphopoietin